Anlon Healthcare Achieves Triple-Digit Growth in Q1 FY27, Strengthens Integrated Pharma Platform

Rajkot, August 01, 2026: Anlon Healthcare Limited, one of India’s leading manufacturers of high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), announced its unaudited consolidated financial results for Q1 FY27, delivering strong growth across revenue and profitability while advancing its transformation into an integrated pharmaceutical company. The Company reported Total Income of ₹87.62 crore, registering 163.02% …

VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India

– VYLOY is the first and only CLDN18.2-targeted treatment approved in the India for adult patients with HER2 negative gastric and gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive – – Central Drugs Standard Control Organization approval was based on the global Phase 3 trials GLOW & SPOTLIGHT where the combination treatment extended median overall survival …